- Home
- DSP vs FDMT Comparison
DSP vs FDMT Comparison
Compare DSP & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- FDMT
- Stock Information
- Founded
- DSP 1999
- FDMT 2013
- Country
- DSP United States
- FDMT United States
- Employees
- DSP N/A
- FDMT N/A
- Industry
- DSP EDP Services
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- DSP Technology
- FDMT Health Care
- Exchange
- DSP Nasdaq
- FDMT Nasdaq
- Market Cap
- DSP 220.3M
- FDMT 192.2M
- IPO Year
- DSP 2021
- FDMT 2020
- Fundamental
- Price
- DSP $13.31
- FDMT $4.31
- Analyst Decision
- DSP Strong Buy
- FDMT Buy
- Analyst Count
- DSP 8
- FDMT 10
- Target Price
- DSP $21.75
- FDMT $32.33
- AVG Volume (30 Days)
- DSP 248.3K
- FDMT 511.6K
- Earning Date
- DSP 08-11-2025
- FDMT 08-07-2025
- Dividend Yield
- DSP N/A
- FDMT N/A
- EPS Growth
- DSP N/A
- FDMT N/A
- EPS
- DSP 0.13
- FDMT N/A
- Revenue
- DSP $306,484,000.00
- FDMT $23,000.00
- Revenue This Year
- DSP $18.36
- FDMT $13,048.65
- Revenue Next Year
- DSP $15.95
- FDMT N/A
- P/E Ratio
- DSP $102.81
- FDMT N/A
- Revenue Growth
- DSP 30.64
- FDMT N/A
- 52 Week Low
- DSP $8.70
- FDMT $2.24
- 52 Week High
- DSP $26.33
- FDMT $28.93
- Technical
- Relative Strength Index (RSI)
- DSP 48.13
- FDMT 57.27
- Support Level
- DSP $12.79
- FDMT $3.68
- Resistance Level
- DSP $13.72
- FDMT $4.13
- Average True Range (ATR)
- DSP 0.61
- FDMT 0.28
- MACD
- DSP 0.05
- FDMT -0.03
- Stochastic Oscillator
- DSP 71.13
- FDMT 67.02
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.